Application of the KEYNOTE-564 trial results to real life population: Which patients with advanced kidney cancer should receive adjuvant pembrolizumabFallara G.,Rosiello G.,Raggi D.,Marandino L.,Malena G.,Basile G.,Colandrea G.,Cignoli D.,Belladelli F.,Musso G.,Cei F.,Bertini R.,Briganti A.,Salonia A.,Montorsi F.,Larcher A.,Necchi A.,Capitanio U.European Urology(2022)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要